Erratum: Hypoxia-inducible factor-1 stimulates postnatal lung development but does not prevent O2-induced alveolar injury (Am J Respir Cell Mol Biol (2015) 52 (448–458) DOI: 10.1165/rcmb.2014-0037OC);Hypoxia-inducible factor-1 stimulates postnatal lung development but does not prevent o2-induced alveolar injury

American Journal of Respiratory Cell and Molecular Biology

Volumn 52, Issue 4, 2015, Pages 448-458

  Tibboel, Jeroen ^a,d   Groenman, Freek A ^a,c   Selvaratnam, Johanna ^a   Wang, Jinxia ^a   Tseu, Irene ^a   Huang, Zhen ^a   Caniggia, Isabella ^b   Luo, Daochun ^a   Tuyl, Minke Van ^a,c   Ackerley, Cameron ^a   Jongste, Johan C De ^d   Tibboel, Dick ^c   Post, Martin ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Alveologenesis; Bronchopulmonary dysplasia; Mice; Vascular development

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; EPHRIN; EPHRIN B2; EPHRIN B4; HYPOXIA INDUCIBLE FACTOR 1; LUNG SURFACTANT; OXYGEN; UNCLASSIFIED DRUG; VASCULOTROPIN; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPITHELIUM; HYPEROXIA; LUNG; LUNG DEVELOPMENT; LUNG FUNCTION; LUNG INJURY; MORPHOMETRICS; MOUSE; NONHUMAN; PERINATAL PERIOD; PROTEIN EXPRESSION; TRANSGENIC MOUSE; UPREGULATION; VASCULARIZATION; WILD TYPE; ANIMAL; C57BL MOUSE; HEK293 CELL LINE; HUMAN; LUNG ALVEOLUS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

MUS; MUS MUSCULUS;

ANIMALS; HEK293 CELLS; HUMANS; HYPEROXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG; MICE, INBRED C57BL; MICE, TRANSGENIC; PULMONARY ALVEOLI; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929659948     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.v63erratum3     Document Type: Erratum

References (40)

1. Groenman FA, Rutter M, Wang J, Caniggia I, Tibboel D, Post M. Effect of chemical stabilizers of hypoxia-inducible factors on early lung development. Am J Physiol Lung Cell Mol Physiol 2007;293:L557-L567.
2. Lee YM, Jeong CH, Koo SY, Son MJ, Song HS, Bae SK, Raleigh JA, Chung HY, Yoo MA, Kim KW. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn 2001;220:175-186.
3. Jobe AH. The new bronchopulmonary dysplasia. Curr Opin Pediatr 2011;23:167-172.
4. Coalson JJ. Pathology of bronchopulmonary dysplasia. Semin Perinatol 2006;30:179-184.
5. Lassus P, Turanlahti M, Heikkilä P, Andersson LC, Nupponen I, Sarnesto A, Andersson S. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 2001;164:1981-1987.
6. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 2002;283:L555-L562.
7. Pappas CT, Obara H, Bensch KG, Northway WH Jr. Effect of prolonged exposure to 80% oxygen on the lung of the newborn mouse. Lab Invest 1983;48:735-748.
8. Alejandre-Alcázar MA, Kwapiszewska G, Reiss I, Amarie OV, Marsh LM, Sevilla-Pé rez J, Wygrecka M, Eul B, Kö brich S, Hesse M, et al. Hyperoxia modulates TGF-beta/BMP signaling in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2007;292:L537-L549.
9. Chang YS, Choi SJ, Sung DK, Kim SY, Oh W, Yang YS, Park WS. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxiainduced lung injury in neonatal rats. Cell Transplant 2011;20:1843-1854.
10. Thébaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, Hashimoto K, Harry G, Haromy A, Korbutt G, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxiainduced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 2005;112:2477-2486.
11. Asikainen TM, Waleh NS, Schneider BK, Clyman RI, White CW. Enhancement of angiogenic effectors through hypoxia-inducible factor in preterm primate lung in vivo. Am J Physiol Lung Cell Mol Physiol 2006;291:L588-L595.
12. Vadivel A, Alphonse RS, Etches N, van Haaften T, Collins JJ, O'Reilly M, Eaton F, Thébaud B. Hypoxia-inducible factors promote alveolar development and regeneration. Am J Respir CellMol Biol 2014;50:96-105.
13. Wiener CM, Booth G, Semenza GL. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 1996;225:485-488.
14. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005;105:659-669.
15. Groenman F, Rutter M, Caniggia I, Tibboel D, Post M. Hypoxiainducible factors in the first trimester human lung. J Histochem Cytochem 2007;55:355-363.
16. Yang J, Wang J, Tseu I, Kuliszewski M, Lee W, Post M. Identification of an 11-residue portion of CTP-phosphocholine cytidylyltransferase that is required for enzyme-membrane interactions. Biochem J. 1997;325:29-38.
17. Hogan BL, Bedington RC, Lacy E. Manipulating the mouse embryo: a laboratory manual. New York: Cold Spring Harb Lab Press; 1994.
18. Tibboel J, Joza S, Reiss I, de Jongste JC, Post M. Amelioration of hyperoxia-induced lung injury using a sphingolipid-based intervention. Eur Respir J 2013;42:776-784.
19. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
20. MacPhee DJ, Mostachfi H, Han R, Lye SJ, Post M, Caniggia I. Focal adhesion kinase is a key mediator of human trophoblast development. Lab Invest 2001;81:1469-1483.
21. Ridsdale R, Post M. Surfactant lipid synthesis and lamellar body formation in glycogen-laden type II cells. Am J Physiol Lung Cell Mol Physiol 2004;287:L743-L751.
22. Glasser SW, Korfhagen TR, Bruno MD, Dey C, Whitsett JA. Structure and expression of the pulmonary surfactant protein SP-C gene in the mouse. J Biol Chem 1990;265:21986-21991.
23. Bridges JP, Lin S, Ikegami M, Shannon JM. Conditional hypoxia inducible factor-1a induction in embryonic pulmonary epithelium impairs maturation and augments lymphangiogenesis. Dev Biol 2012;362:24-41.
24. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16:1466-1471.
25. McGowan SE, Torday JS. The pulmonary lipofibroblast (lipid interstitial cell) and its contributions to alveolar development. Annu Rev Physiol 1997;59:43-62.
26. Roth-Kleiner M, Post M. Similarities and dissimilarities of branching and septation during lung development. Pediatr Pulmonol 2005;40:113-134.
27. Thébaud B. Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology 2007;91:291-297.
28. Abman SH. Bronchopulmonary dysplasia: "a vascular hypothesis". Am J Respir Crit Care Med 2001;164:1755-1756.
29. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006;367:1421-1431.
30. Ng Y-S, Krilleke D, Shima DT. VEGF function in vascular pathogenesis. Exp Cell Res 2006;312:527-537.
31. Galambos C, Ng Y-S, Ali A, Noguchi A, Lovejoy S, D'Amore PA, DeMello DE. Defective pulmonary development in the absence of heparin-binding vascular endothelial growth factor isoforms. Am J Respir Cell Mol Biol 2002;27:194-203.
32. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001;220:112-121.
33. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164:1971-1980.
34. Kunig AM, Balasubramaniam V, Markham NE, Seedorf G, Gien J, Abman SH. Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia. Am J Physiol Lung Cell Mol Physiol 2006;291:L1068-L1078.
35. Hosford GE, Olson DM. Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung. Am J Physiol Lung Cell Mol Physiol 2003;285:L161-L168.
36. Benderro GF, Sun X, Kuang Y, Lamanna JC. Decreased VEGF expression and microvascular density, but increased HIF-1 and 2a accumulation and EPO expression in chronic moderate hyperoxia in the mouse brain. Brain Res 2012;1471:46-55.
37. Ito Y, Ahmad A, Kewley E, Mason RJ. Hypoxia-inducible factor regulates expression of surfactant protein in alveolar type II cells in vitro. Am J Respir Cell Mol Biol 2011;45:938-945.
38. Schmidt R, Ruppert C, Markart P, Lü bke N, Ermert L, Weissmann N, Breithecker A, Ermert M, Seeger W, Gü nther A. Changes in pulmonary surfactant function and composition in bleomycininduced pneumonitis and fibrosis. Toxicol Appl Pharmacol 2004;195:218-231.
39. Schmidt R, Markart P, Ruppert C, Wygrecka M, Kuchenbuch T, Walmrath D, Seeger W, Guenther A. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res 2007;8:55.
40. Ridsdale R, Roth-Kleiner M, D'Ovidio F, Unger S, Yi M, Keshavjee S, Tanswell AK, Post M. Surfactant almitoylmyristoylphosphatidylcholine is a marker for alveolar size during disease. Am J Respir Crit Care Med 2005;172:225-232.